ReviewOncotarget2017

Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials.

Jian-Wei Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.